Scientific deep-dive

Two Studies, One Comparison, Two Answers

One real-world study found no cardiovascular difference between the two drugs. Another found semaglutide 29% better. Working out why they disagree is more useful than either answer.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·2 citations

Two real-world studies published in 2026 compared semaglutide against tirzepatide on cardiovascular outcomes. One found no meaningful difference. The other found semaglutide reduced major cardiovascular events by 29%.[1][2] Both used large databases and careful matching. Working out why they disagree is more useful than either answer.

The two results

Two real-world comparisons of the same two drugs on cardiovascular endpoints.
StudyPopulationResult
Trial-emulation studyType 2 diabetesTirzepatide vs semaglutide, HR 1.06 (95% CI 0.95–1.18) — comparable
Claims-database studyOverweight or obesity with cardiovascular disease, without diabetesSemaglutide vs tirzepatide, HR 0.71 (p=0.046) and 0.78 (p=0.040)

Reason one: they studied different people

This is the most straightforward explanation and possibly sufficient on its own. One study looked at people with type 2 diabetes. The other looked at people with overweight or obesity and established atherosclerotic cardiovascular disease but no diabetes.

Those groups have different baseline risks, different reasons for being prescribed either drug, and different competing causes of cardiovascular events. There is no rule that two drugs must rank identically in both.

Reason two: one result is marginal

The p-values in the claims study are 0.046 and 0.040. Those clear the conventional threshold by a hair. A finding at p=0.046 is one that would frequently not replicate, and it should be read as “possibly something” rather than as a demonstration.

Reason three, and the one to learn from

The claims study also ran a per-protocol analysis, censoring patients when they had a gap in therapy of more than 30 days. In that analysis the hazard ratio moved from 0.71 to 0.43, and from 0.78 to 0.57. The paper reports that far more dramatic effect as support for its main result.

An effect that grows sharply once you exclude the people who stopped is a warning sign, not a confirmation.

Excluding people who discontinue removes a specific kind of patient: the ones who could not tolerate the drug, could not afford it, got sicker, or were hospitalized. The people who leave systematically have worse trajectories than the people who stay. Removing them makes any drug look better, and it makes the drug with better persistence look better still.

Persistence can differ sharply between GLP-1 drugs and formulations. A UK cohort measured it and found discontinuation ran from 36.9% to 55.8% depending on the drug, though tirzepatide was not among them. A comparison that censors on discontinuation is partly measuring that.

Which to believe

The trial-emulation study has the stronger methodology. Before extending to a broader population, it first reproduced the reference randomized trials, checking that its methods recovered the known answers on every individual endpoint except all-cause mortality in one trial. Only then did it apply those methods to new questions.[1]

That is calibration, and it is rare. Most observational studies ask you to trust their design; this one demonstrated it against a known answer first. Its conclusion, comparable cardiovascular benefit between the two drugs in clinical practice, is the one we would weight more heavily.

None of this makes the second study worthless. It asked a different question in a different population, and the possibility that the drugs differ in people without diabetes is still open. What it does not support is choosing between the two drugs on cardiovascular grounds today. Pooling studies like these does not settle it either: a meta-analysis of 323,439 patients found no significant cardiovascular difference between tirzepatide and the GLP-1 drugs it competes with, and the studies it combined disagreed with each other almost completely.For weight, the comparison runs the other way, as real-world weight data shows.

Frequently Asked Questions

The evidence disagrees with itself. A trial-emulation study in type 2 diabetes found no meaningful difference, at a hazard ratio of 1.06. A claims study in people with overweight or obesity and cardiovascular disease but no diabetes found semaglutide 29% better, at marginal significance.
Three reasons here: they studied different populations, one result sits barely over the significance threshold at p=0.046, and that study's result grew much larger in a per-protocol analysis that excludes people who stopped taking the drug.
They are not random. People who discontinue are disproportionately those who could not tolerate the drug, could not afford it, or got sicker. Removing them flatters any drug, and flatters the drug with better persistence most.
The trial-emulation one has the better methodology, because it first reproduced the known results of the reference randomized trials before extending to new questions. That calibration step is rare and it is what makes its conclusion of comparable cardiovascular benefit more credible.
Not on cardiovascular grounds. The better-designed evidence says the two are comparable there. Weight loss is a different question, where real-world data favors tirzepatide, and tolerability differs between them as well.

References

  1. 1.Krüger N, Schneeweiss S, Desai RJ, et al. Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice Nature Medicine. 2026. PMID: 41207920.
  2. 2.Wilson L, Zhao Z, Divino V, et al. Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world Diabetes, Obesity and Metabolism. 2026. PMID: 41491349.

GLP-1 Drugs and Blood Pressure: How Much It Falls, and What Happens When You Stop

On the FDA labels, systolic blood pressure fell about 4 to 7 points more than placebo on tirzepatide and 3 to 5 on semaglutide. 24-hour monitoring confirmed it, weight loss explained most of it, and in the withdrawal trials much of it came back.

8 min read

Semaglutide and Peripheral Artery Disease: The Label, the Options and Coverage

STRIDE showed semaglutide 1 mg improved walking distance in type 2 diabetes with PAD, and Novo Nordisk filed for a US label change in 2025. Ozempic's label still lists no PAD use, but PAD already counts as cardiovascular disease on the Ozempic and Wegovy labels.

7 min read

GLP-1s and Atrial Fibrillation: Reading a 42% Headline

A meta-analysis of ten trials in 12,651 patients found a 42% lower risk of new atrial fibrillation on semaglutide. None of those trials was designed to measure it, and the absolute numbers were never published.

6 min read

Semaglutide and Days Spent in Hospital

A prespecified analysis of SELECT found hospital days falling from 176.2 to 157.2 per 100 patient-years. It is a modest number from a randomized trial, which is what makes it trustworthy.

5 min read

Mounjaro Heart Protection: What SURPASS-CVOT Found and What FDA Approved

In August 2026 FDA gave Mounjaro a heart-risk indication for high-risk adults with type 2 diabetes. SURPASS-CVOT found 12.2% vs 13.1% major heart events against Trulicity: non-inferior, not superior. Zepbound has no heart indication; SURMOUNT-MMO is due in 2027.

7 min read

How Far You Can Walk

Peripheral artery disease stops people walking, and almost nothing improves it. A trial of 792 people measured actual walking distance, and the spread matters as much as the median.

6 min read

Where to get tirzepatide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.4

Bodybuilding Health+

Seeing what it charges before you answer any medical questions

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

7.3

Found

People who want clinician visits billed to commercial insurance, with compounded medication in the plan price

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →